{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:02:23Z","timestamp":1791846143342,"version":"4.3.4"},"reference-count":57,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Urologia"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:p>Bladder cancer is second among the most common urothelial malignancy and one of the most expensive in terms of treatment. Localized bladder cancer is classified into non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). First line approach for treatment of NMIBC is transurethral resection of bladder tumor (TURBT) followed by intravesical instillation of immuno\/chemotherapeutic agents to prevent or delay recurrence or progression. Historically intravesical Bacillus Calmette Geurin (BCG) instillation has been a mainstay of therapy for NMIBC post-TURBT. Commonly followed drug delivery is intravesical instillation that maximizes exposure of the drug to the lesion and minimizes systemic side effects. Gemcitabine used in bladder cancer due to its pharmacological properties making it appropriate for intravesical instillation. Limitations of intravesical instillation is low bladder permeability leading to decreased drug concentration in bladder tissues and frequent urination causing drug wash out or dilution reducing the effect of treatment. Effective intravesical therapy depends on the penetration of the drug into the tumor. TAR200 is a novel drug delivery system that facilitates sustained release of continuous low dose gemcitabine over an indwelling period providing a uniform concentration of drug after each voiding cycle and exposure of drug to the bladder tumor. There are completed and ongoing clinical trials to evaluate the efficacy of TAR200 alone or in combination with other chemotherapeutic agents in NMIBC and MIBC. FDA has granted breakthrough therapy designation (BTD) for TAR-200 in December 2023. This review highlights the potential of TAR-200 and clinical trials that improve bladder cancer treatment outcome.<\/jats:p>","DOI":"10.1177\/03915603251319133","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T05:25:15Z","timestamp":1739251515000},"page":"243-251","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["TAR-200: Investigational intravesical drug delivery system for bladder cancer"],"prefix":"10.1177","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9929-4449","authenticated-orcid":false,"given":"Muhammed","family":"Munavvir","sequence":"first","affiliation":[{"name":"Department of Urology, Yenepoya Medical College Hospital, Derlakatte, Mangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujeeburahiman","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altaf","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav Das","family":"Debashish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2006.03.062"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03262330"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.010"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/551S33a"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30512-8"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.06.045"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2003.04655.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)64043-8"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.01.009"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.12.018"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.05.037"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00733-z"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29387"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.10.120"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj970"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00610-9"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000002189"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160072"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21631"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.08.038"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.03.084"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00613"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.06.025"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00282.2013"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00709-010-0112-1"},{"key":"e_1_3_3_32_2","first-page":"1","article-title":"Properties of the urothelium that establish the blood\u2013urine barrier and their implications for drug delivery","volume":"56","author":"Lasi\u010d E","year":"2015","unstructured":"Lasi\u010d E, Vi\u0161njar T, Kreft ME. Properties of the urothelium that establish the blood\u2013urine barrier and their implications for drug delivery. Rev Physiol Biochem Pharmacol 2015; 56: 1\u201329.","journal-title":"Rev Physiol Biochem Pharmacol"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.022"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.5301\/uro.5000184"},{"key":"e_1_3_3_35_2","first-page":"493","article-title":"Bladder surface glycosaminoglycans is a human epithelial permeability barrier","volume":"171","author":"Lilly JD","year":"1990","unstructured":"Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet 1990; 171: 493.","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13020166"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-019-0220-4"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2016.13"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.12.090"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14872"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.11.015"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.01.013"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000350"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1115\/1.4026711"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003804"},{"key":"e_1_3_3_46_2","volume-title":"Urologic oncology: seminars and original investigations","author":"Daneshmand S","year":"2022","unstructured":"Daneshmand S, Brummelhuis IS, Pohar KS, et al. The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial. In Urologic oncology: seminars and original investigations 2022 (Vol. 40, No. 7, pp. 344\u2013e1). Elsevier."},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.09.006"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160056"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-LB-122"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2024.01.013"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003195"},{"key":"e_1_3_3_52_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04640623"},{"key":"e_1_3_3_53_2","unstructured":"TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non\u2013muscle-invasive bladder cancer. 2024 [cited 2024 may 8]. Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/tar-200-monotherapy-shows-greater-than-80-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer"},{"key":"e_1_3_3_54_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04658862"},{"key":"e_1_3_3_55_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04919512"},{"key":"e_1_3_3_56_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05714202"},{"key":"e_1_3_3_57_2","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT06211764"},{"key":"e_1_3_3_58_2","unstructured":"TAR-210 results show 90% recurrence-free survival and 90% complete response in patients with high-risk and intermediate-risk non\u2013muscle-invasive bladder cancer respectively. 2024 [cited on 2024 may 13] Available from: https:\/\/www.jnj.com\/media-center\/press-releases\/tar-210-results-show-90-recurrence-free-survival-and-90-complete-response-in-patients-with-high-risk-and-intermediate-risk-non-muscle-invasive-bladder-cancer-respectively"}],"container-title":["Urologia Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251319133","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03915603251319133","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03915603251319133","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T04:39:41Z","timestamp":1747197581000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03915603251319133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1177\/03915603251319133"],"URL":"https:\/\/doi.org\/10.1177\/03915603251319133","relation":{},"ISSN":["0391-5603","1724-6075"],"issn-type":[{"value":"0391-5603","type":"print"},{"value":"1724-6075","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}